PPAR Market: Competitive Landscape, Pipeline, and Market Analysis 2023

PPARs (Peroxisome proliferator-activated receptors) are a group of nuclear receptor proteins involved in regulating gene expression and various physiological processes. They act as transcription factors, modulating the expression of genes involved in metabolism, inflammation, and cell differentiation. PPARs function through binding to specific PPAR sequences, forming heterodimers with retinoid X receptors (RXRs), and regulating the transcription of target genes. PPARs have been extensively studied for their therapeutic potential in metabolic disorders such as diabetes, dyslipidemia, and obesity due to their involvement in glucose and lipid metabolism. They are also investigated in cardiovascular diseases, including atherosclerosis and heart failure, as well as in inflammation, neurodegenerative disorders, and cancer. According to the World Health Organization (WHO), diabetes affects an estimated 60 million people in Europe and 34 million people in the United States. Obesity rates have reached 23% in Europe and 36% in the United States, contributing to a significant increase in the incidence of related metabolic disorders. Cardiovascular diseases are the leading cause of death in Europe, accounting for approximately 4 million deaths per year. In the United States, cardiovascular diseases are responsible for more than 840,000 deaths annually, making them a major health concern.

The growth of the PPAR market is driven by factors such as the increasing prevalence of metabolic disorders, the aging population, and the demand for more effective treatment options. Additionally, advancements in drug development technologies and the presence of key pharmaceutical companies investing in PPAR research contribute to market growth. Companies such as Roche, Ipsen, Daiichi Sankyo, NeuroBo, CymaBay, Astellas, Daiichi Sankyo, Santen, Nogra Pharma, Reneo Pharma, Inventiva, Ability Pharma, Minoryx, FSD Pharma, Coherus Biosci, OMEICOS, Metabolic Solutions, Astellas, Alanza, Hanmi, Sanofi. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Otsuka is currently conducting a clinical trial of the drug SGI-110 for the treatment of leukemia.

Key Developments

• In May 2021, Ipsen released efficacy and safety data from a phase III trial of Elafibranor in primary biliary cirrhosis.
• In Oct 2022, Kowa Pharmaceuticals got preregistration for Parmodia in Dyslipidaemias in Malaysia.

Approved PPAR molecules

• Pioglitazone
• Rosiglitazone
• Fenofibrate
• Fenofibrate nanoparticle formulation
• Duvie (lobeglitazone)
• Fenofibric acid

PPAR Pipeline Molecules

• Aleglitazar (R1439)
• Elafibranor (GFT505)
• Efatutazone (CS-7017)
• Gemcabene (CI-1027)
• Seladelpar (MBX-8025)
• Arhalofenate (MBX-102)
• Bocidelpar (MA-0211)
• Rivoglitazone (CS-011)
• GED 0507-34-Levo
• REN001
• Lanifibranor (IVA337)
• ABTL0812
• Indeglitazar (PLX204)
• Pemafibrate ER (K-877-ER)
• EHP-101
• GSK376501
• Endurobol (GW501516)
• Leriglitazone (MIN-102)
• Micro-palmitoylethanolamide (FSD 201)
• AMG 131
• OMT-28
• Mitoglitazone (MSDC-0160)
• ASP1128
• ATx08-001
• Fenocid (fenofibric acid)
• PN-2034
• T3D-959
• Pioglitazone SR (AD-4833 SR)
• BEBT-503
• CB-0406
• DSP-8658
• FHL-301
• KDT501          

Clinical Activity and Development of PPAR

• In the PPAR space, more than 20 companies are conducting more than 400 clinical trials in this category of drugs. For instance,
• In May 2021, Chong Kun Dang Pharmaceutical completed a phase I trial of Duvie in Type 2 Diabetes Mellitus (Combination therapy) in South Korea
• In March 2023, Ipsen completes a phase I pharmacokinetics trial (In volunteers) of Elafibranorin USA.
• In May 2023, Kowa Pharmaceutical initiated Phase-III clinical trials of Parmodia in Hypercholesterolaemia (Second-line therapy or greater) in Japan.